References
- Korean Society for the Study of Obesity. Clinical practice guidelines for obesity, 8th edition. 2022:1-17.
- Korean Society for the Study of Obesity. 2021 obesity fact sheet. Available from https://www.kosso.or.kr/file/2021_Obesity_Fact_Sheet_web_kor.pdf?v=2307210355. Accessed July 21, 2023.
- Korean Diabetes Association. Clinical practice guidelines for diabetes. 2023:21-183.
- Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705. https://doi.org/10.1016/S0140-6736(06)69705-5
- Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994;107(6):1848-55. https://doi.org/10.1016/0016-5085(94)90831-1
- Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50(3):609-13. https://doi.org/10.2337/diabetes.50.3.609
- Clarke T. FDA approves Novo Nordisk diabetes drug Ozempic. Reuters. 2017. Available from https://www.reuters.com/article/idUSKBN1DZ2O8/. Accessed December 18, 2023.
- U.S. Food and Drug Administration. FDA approves new drug treatment for chronic weight management, first since 2014. 2021. Available from https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-managementfirst-2014. Accessed December 18, 2023.
- Ministry of Food and Drug Safety. Ozempic prefilled pen (semaglutide). Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202201737aupdateTs2023-07-03%2017:55:00.0b. Accessed December 18, 2023.
- Ministry of Food and Drug Safety. Wegovy prefilled pen (semaglutide). Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202301387aupdateTs2023-12-15%2013:45:40.397763b. Accessed December 18, 2023.
- U.S. Food and Drug Administration. FDA approves first oral GLP-1 treatment for type 2 diabetes. 2019. Available from https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes. Accessed December 18, 2023.
- Ministry of Food and Drug Safety. Rybelsus (semaglutide). Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202201785aupdateTs2023-11-09%2011:24:14.969223b. Accessed December 18, 2023.
- Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 2017;5(4):251-60. https://doi.org/10.1016/S2213-8587(17)30013-X
- Rodbard HW, Lingvay I, Reed J, et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J Clin Endocrinol Metab 2018;103(6):2291-301. https://doi.org/10.1210/jc.2018-00070
- Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2019;7(5):356-67. https://doi.org/10.1016/S2213-8587(19)30066-X
- Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial. Diabetes Care 2018;41(2):258-66. https://doi.org/10.2337/dc17-0417
- Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 2018;6(4):275-86. https://doi.org/10.1016/S2213-8587(18)30024-X
- Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab 2020;46(2):100-9. https://doi.org/10.1016/j.diabet.2019.101117
- Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol 2019;7(11):834-44. https://doi.org/10.1016/S2213-8587(19)30311-0
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA 2021;325(14):1414-25. https://doi.org/10.1001/jama.2021.3224
- Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA 2021;325(14):1403-13. https://doi.org/10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28(10):2083-91. https://doi.org/10.1038/s41591-022-02026-4
- Weghuber D, Barrett T, Barrientos-Perez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med 2022;387(24):2245-57. https://doi.org/10.1056/NEJMoa2208601
- Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA 2022;327(2):138-50. https://doi.org/10.1001/jama.2021.23619
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385(6):503-15. https://doi.org/10.1056/NEJMoa2107519
- McGowan BM, Houshmand-Oeregaard A, Laursen PN, Zeuthen N, Baker-Knight J. Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial. Obesity (Silver Spring) 2023;31(4):990-28.
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022;24(8):1553-64. https://doi.org/10.1111/dom.14725
- Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care 2019;42(9):1724-32. https://doi.org/10.2337/dc19-0749
- Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol 2019;7(7):515-27. https://doi.org/10.1016/S2213-8587(19)30192-5
- Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 2019;394(10192):39-50. https://doi.org/10.1016/S0140-6736(19)31271-1
- Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 trial. Diabetes Care 2019;42(12):2272-81. https://doi.org/10.2337/dc19-0883
- Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol 2020;8(5):392-406. https://doi.org/10.1016/S2213-8587(20)30074-7
- Yamada Y, Katagiri H, Hamamoto Y, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes Endocrinol 2020;8(5):377-91. https://doi.org/10.1016/S2213-8587(20)30075-9
- Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: The PIONEER 8 trial. Diabetes Care 2019;42(12):2262-71. https://doi.org/10.2337/dc19-0898
- Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;402(10403):705-19.
- American Diabetes Association. Standards of care in diabetes - 2023. Diabetes Care 2023;46(Suppl. 1).
- Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan - 2022 update. Endocr Pract 2022;28(10):923-1049.
- Korean Diabetes Association. Clinical practice guidelines for diabetes, 7th edition. 2021:89.
- Korean Diabetes Association. Clinical practice guidelines for diabetes, 8th edition. 2023:125.
- Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology 2022;163(5):1198-225. https://doi.org/10.1053/j.gastro.2022.08.045
- DrFirst. Ozempic this, Wegovy that: no matter what you call it, semaglutide is having a moment. 2023. Available from https://drfirst.com/press-releases/ozempic-this-wegovy-that-no-matter-what-youcall-it-semaglutide-is-having-a-moment/. Accessed February 13, 2024.
- McPhillips D. CNN exclusive: prescriptions for popular diabetes and weight-loss drugs soared, but access is limited for some patients. CNN. 2023. Available from https://edition.cnn.com/2023/09/27/health/semaglutide-equitable-access/index.html. Accessed February 13, 2024.
- American Society of Health-System Pharmacists. Semaglutide injection. 2024. Available from https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=813&loginreturnUrl=SSOCheckOnly. Accessed February 13, 2024.
- Klein HE. An ongoing crisis: semaglutide shortage raises dual concerns for obesity and diabetes treatment. American Journal of Managed Care. 2023. Available from https://www.ajmc.com/view/an-ongoing-crisis-semaglutide-shortage-raises-dual-concerns-for-obesity-and-diabetes-treatment. Accessed February 13, 2024.
- Leitner DR, Fruhbeck G, Yumuk V, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies - EASO can lead the way. Obes Facts 2017;10(5):483-92. https://doi.org/10.1159/000480525
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389(24):2221-32. https://doi.org/10.1056/NEJMoa2307563
- Wegovy (semaglutide) [Package Insert] Novo Nordis; Bagsvaerd, Denmark: 2022.
- Park ET. Finally, a survey?...Is misuse of 'obesity treatment' okay? Medipana. 2023. Available from: https://www.medipana.com/article/view.php?news_idx=317626. Accessed February 29, 2024.